Bruce M. Hendry
YOU?
Author Swipe
View article: #1916 Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the phase 2 SPARTACUS trial
#1916 Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors in adults with IgA nephropathy in the phase 2 SPARTACUS trial Open
Background and Aims Sparsentan (SPAR) is a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA) approved in the US and Europe for adults with immunoglobulin A nephropathy (IgAN). In patients with IgAN, SPAR showed…
View article: #1920 Effects of sparsentan after maximized angiotensin receptor blocker (ARB) treatment in patients with IgA nephropathy (IgAN) in the PROTECT trial
#1920 Effects of sparsentan after maximized angiotensin receptor blocker (ARB) treatment in patients with IgA nephropathy (IgAN) in the PROTECT trial Open
Background and Aims Sparsentan is a non-immunosuppressive, dual endothelin angiotensin receptor antagonist (DEARA) indicated to slow kidney function decline in adults with IgAN. The PROTECT trial demonstrated superior proteinuria reduction…
View article: #2883 Kidney outcomes and effects of proteinuria in Alport syndrome: a longitudinal analysis of 1175 patients from the UK National Registry of Rare Kidney Diseases (RaDaR)
#2883 Kidney outcomes and effects of proteinuria in Alport syndrome: a longitudinal analysis of 1175 patients from the UK National Registry of Rare Kidney Diseases (RaDaR) Open
Background and Aims Alport syndrome (AS) is often characterised by pathogenic variants in type IV collagen genes COL4A3/4/5. Previous genotype-phenotype studies have shown patients with certain genotypes reach kidney failure (KF) at a youn…
View article: #272 Sparsentan reduces glomerular dysfunction and proteinuria in a rat model of serum-factor-induced nephrotic syndrome
#272 Sparsentan reduces glomerular dysfunction and proteinuria in a rat model of serum-factor-induced nephrotic syndrome Open
Background and Aims Glomerular function is dependent on the three-layer structure of the glomerular filtration barrier (GFB): glomerular endothelial cells and their surface glycocalyx, the glomerular basement membrane and podocytes. Protei…
View article: Spotlighting healthcare frontline workers´ perceptions on artificial intelligence across the globe
Spotlighting healthcare frontline workers´ perceptions on artificial intelligence across the globe Open
View article: Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria Open
Key Points In nephrotic syndrome, diagnosis was associated with kidney failure risk: very high in monogenic cases, substantial in FSGS, and less but not zero in minimal change disease. Early control of proteinuria was associated with lower…
View article: The humanistic burden of focal segmental glomerulosclerosis on patients and care-partners in the United States
The humanistic burden of focal segmental glomerulosclerosis on patients and care-partners in the United States Open
View article: Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids
Framework for precision medicine in focal segmental glomerulosclerosis: Translation of sparsentan-responsive genes in a rat model to kidney disease associated proteins in biofluids Open
Sparsentan, a dual endothelin receptor A inhibitor and angiotensin blocker, reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) in Phase II and Phase III studies. However, the estimated glomerular filtration rate…
View article: WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT Open
View article: The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States
The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States Open
View article: The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States
The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States Open
US adults with IgAN and their care partners experience impairments to mental and physical HRQoL and heightened levels of depression and anxiety, underscoring the need for effective IgAN therapies and care-partner support.
View article: Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis
Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis Open
Our results indicated that various IgAN health states are associated with impaired health status, with substantial utility decrements related to disease progression, elevated proteinuria, and nephrotic syndrome.
View article: Long-term outcomes of patients with IgA nephropathy in the German CKD cohort
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort Open
Background The importance of albuminuria as opposed to proteinuria in predicting kidney outcomes in primary immunoglobulin A nephropathy (IgAN) is not well established. Methods From 2010 to 2012, 421 patients with biopsy-proven IgAN have b…
View article: Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease Open
Simultaneous inhibition of angiotensin II AT1 and endothelin ETA receptors has emerged as a promising approach for treatment of chronic progressive kidney disease. This therapeutic approach has been advanced by the introduction of sparsent…
View article: #367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison
#367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison Open
Background and Aims Immunoglobulin A (IgA) nephropathy is a rare kidney disorder characterized by deposition of IgA in the glomeruli causing progressive loss of kidney function and increased risk of kidney failure. In the absence of a head…
View article: #368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd
#368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd Open
Background and Aims Immunoglobulin A nephropathy (IgAN) is a rare kidney disorder characterized by deposition of IgA in the glomeruli leading to an increased risk of kidney failure. The PROTECT clinical trial in IgAN was designed to determ…
View article: #901 Natural history of idiopathic nephrotic syndrome: the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
#901 Natural history of idiopathic nephrotic syndrome: the UK National RaDaR Idiopathic Nephrotic Syndrome Cohort Open
Background and Aims Idiopathic nephrotic syndrome (INS) is an important class of proteinuric renal disease leading to kidney failure (KF). Here we describe the natural history of INS and congenital nephrotic syndrome (NS) using the UK Nati…
View article: #457 Sparsentan has direct effects on the glomerular capillary wall to attenuate increased permeability after exposure to nephrotic syndrome plasma
#457 Sparsentan has direct effects on the glomerular capillary wall to attenuate increased permeability after exposure to nephrotic syndrome plasma Open
Background and Aims The glomerular endothelial glycocalyx (eGlx), a luminal layer of proteoglycans, glycoproteins and glycolipids, forms the first part of the glomerular filtration barrier (GFB). Nephrotic syndrome (NS) describes a group o…
View article: Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort Open
Background Focal segmental glomerulosclerosis (FSGS) can lead to kidney failure in adults. This study examines the progression of FSGS in the German Chronic Kidney Disease (GCKD) cohort. Methods The GCKD study (N = 5217), a prospective coh…
View article: WCN24-846 SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY
WCN24-846 SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY Open
In the PROTECT study, sparsentan, which targets both the endothelin type A (ETAR) and angiotensin type 1 (AT1R) receptors, reduced proteinuria vs active comparator in immunoglobulin A nephropathy (IgAN), with minimal changes in fluid statu…
View article: Differentiating primary and secondary FSGS using non-invasive urine biomarkers
Differentiating primary and secondary FSGS using non-invasive urine biomarkers Open
Background Focal segmental glomerulosclerosis (FSGS) is divided into genetic, primary (p), uncertain cause, and secondary (s) forms. The subclasses differ in management and prognosis with differentiation often being challenging. We aimed t…
View article: #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY
#4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY Open
Background and Aims Reduction in proteinuria is associated with lower risk of kidney failure (KF) in IgA nephropathy (IgAN) (Thompson et al, 2019). In phase 3 randomized controlled trials in IgAN patients, a treatment effect on proteinuria…
View article: #3067 ALPORT SYNDROME NATURAL HISTORY FROM THE RADAR REGISTRY: ASSOCIATIONS WITH GENE, VARIANT TYPE AND SEX
#3067 ALPORT SYNDROME NATURAL HISTORY FROM THE RADAR REGISTRY: ASSOCIATIONS WITH GENE, VARIANT TYPE AND SEX Open
Background and Aims Alport Syndrome (AS) is caused by pathogenic variants in COL4A3, COL4A4 & COL4A5 genes. The clinical course of AS can be highly variable, depending on gene affected, mutation type and Male (M) or Female (F) sex. Protein…
View article: #4499 MATCHING-ADJUSTED INDIRECT COMPARISON OF SPARSENTAN VS DELAYED-RELEASE FORMULATION BUDESONIDE FOR PROTEINURIA REDUCTION IN ADULTS WITH IGA NEPHROPATHY
#4499 MATCHING-ADJUSTED INDIRECT COMPARISON OF SPARSENTAN VS DELAYED-RELEASE FORMULATION BUDESONIDE FOR PROTEINURIA REDUCTION IN ADULTS WITH IGA NEPHROPATHY Open
Background and Aims Immunoglobulin A (IgA) nephropathy is a rare kidney disorder characterized by deposition of IgA in the glomeruli and associated with a reduction in renal function and increased risk of kidney failure [1,2]. In the absen…
View article: #4778 THE NATURAL HISTORY OF IGA NEPHROPATHY IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT
#4778 THE NATURAL HISTORY OF IGA NEPHROPATHY IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT Open
Background and Aims Primary IgA nephropathy (IgAN) is the most common form of glomerulonephritis and a major cause of kidney failure. Here we describe the natural history of individuals with IgAN in the German Chronic Kidney Disease (GCKD)…
View article: #3057 OUTCOMES IN SRNS (FSGS) PATIENTS IN THE UK RADAR IDIOPATHIC NEPHROTIC SYNDROME REGISTRY AND THEIR RELATIONSHIP WITH TIME-AVERAGED PROTEINURIA
#3057 OUTCOMES IN SRNS (FSGS) PATIENTS IN THE UK RADAR IDIOPATHIC NEPHROTIC SYNDROME REGISTRY AND THEIR RELATIONSHIP WITH TIME-AVERAGED PROTEINURIA Open
Background and Aims Idiopathic Steroid Resistant Nephrotic Syndrome, SRNS (incorporating FSGS) is an important cause of proteinuric renal disease leading to kidney failure. Here we describe the outcomes of SRNS using the UK National Regist…
View article: #5142 THE NATURAL HISTORY OF FSGS IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT
#5142 THE NATURAL HISTORY OF FSGS IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT Open
Background and Aims FSGS is a heterogenic glomerular disease and a common cause of kidney failure in adults. Here we describe the natural history of individuals with FSGS in the German Chronic Kidney Disease (GCKD) cohort. Method From 2010…
View article: Long-Term Outcomes in IgA Nephropathy
Long-Term Outcomes in IgA Nephropathy Open
Background IgA nephropathy can progress to kidney failure, and risk assessment soon after diagnosis has advantages both for clinical management and the development of new therapeutics. We present relationships among proteinuria, eGFR slope…
View article: Stimulated phosphorylation of ERK in mouse kidney mesangial cells is dependent upon expression of Cav3.1
Stimulated phosphorylation of ERK in mouse kidney mesangial cells is dependent upon expression of Cav3.1 Open
View article: Stimulated Phosphorylation of ERK in Mouse Kidney Mesangial Cells is Dependent Upon Expression of Cav3.1
Stimulated Phosphorylation of ERK in Mouse Kidney Mesangial Cells is Dependent Upon Expression of Cav3.1 Open
Background: T-type calcium channels (TTCC) are low voltage activated channels that are widely expressed in the heart, smooth muscle and neurons. They are known to impact on cell cycle progression in cancer and smooth muscle cells and more …